West Pharmaceutical Servs Analyst Ratings
West Pharmaceutical Servs Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/21/2023 | 7.02% | Keybanc | $385 → $415 | Maintains | Overweight |
| 07/28/2023 | -0.71% | Keybanc | $375 → $385 | Maintains | Overweight |
| 07/17/2023 | 8.31% | Stephens & Co. | $400 → $420 | Maintains | Overweight |
| 06/16/2023 | 4.44% | B of A Securities | $390 → $405 | Upgrades | Neutral → Buy |
| 04/11/2023 | 3.15% | Stephens & Co. | $330 → $400 | Upgrades | Equal-Weight → Overweight |
| 02/17/2023 | -3.29% | Keybanc | $315 → $375 | Maintains | Overweight |
| 12/14/2022 | -35.53% | Deutsche Bank | → $250 | Initiates Coverage On | → Hold |
| 12/02/2022 | -18.77% | Keybanc | $350 → $315 | Maintains | Overweight |
| 11/30/2022 | -35.53% | UBS | → $250 | Initiates Coverage On | → Neutral |
| 10/28/2022 | -35.53% | B of A Securities | $385 → $250 | Downgrades | Buy → Neutral |
| 10/28/2022 | -9.74% | Keybanc | $400 → $350 | Maintains | Overweight |
| 07/29/2022 | -11.03% | Stephens & Co. | $330 → $345 | Maintains | Equal-Weight |
| 04/29/2022 | 5.73% | B of A Securities | $475 → $410 | Maintains | Buy |
| 04/29/2022 | 3.15% | Keybanc | $475 → $400 | Maintains | Overweight |
| 09/15/2021 | 32.81% | B of A Securities | $450 → $515 | Maintains | Buy |
| 07/30/2021 | 3.15% | Stephens & Co. | $360 → $400 | Maintains | Equal-Weight |
| 07/30/2021 | 22.5% | Keybanc | $350 → $475 | Maintains | Overweight |
| 04/30/2021 | -12.32% | Stephens & Co. | $315 → $340 | Maintains | Equal-Weight |
| 02/19/2021 | -18.77% | Stephens & Co. | $300 → $315 | Maintains | Equal-Weight |
| 11/10/2020 | -9.74% | Keybanc | → $350 | Initiates Coverage On | → Overweight |
| 10/14/2020 | -22.63% | Stephens & Co. | → $300 | Initiates Coverage On | → Equal-Weight |
| 04/24/2020 | — | B of A Securities | Upgrades | Underperform → Neutral | |
| 12/12/2019 | — | B of A Securities | Downgrades | Neutral → Underperform | |
| 07/26/2019 | — | B of A Securities | Upgrades | Underperform → Neutral | |
| 05/01/2019 | — | Jefferies | Downgrades | Buy → Hold | |
| 04/23/2019 | — | William Blair | Initiates Coverage On | → Outperform |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 2023年08月21日 | 7.02% | KeyBanc | $385→$415 | 維護 | 超重 |
| 07/28/2023 | -0.71% | KeyBanc | $375→$385 | 維護 | 超重 |
| 07/17/2023 | 8.31% | 斯蒂芬斯公司 | $400→$420 | 維護 | 超重 |
| 06/16/2023 | 4.44% | B of A證券 | $390→$405 | 升級 | 中性→購買 |
| 04/11/2023 | 3.15% | 斯蒂芬斯公司 | $330→$400 | 升級 | 等重→超重 |
| 02/17/2023 | -3.29% | KeyBanc | $315→$375 | 維護 | 超重 |
| 2022年12月14日 | -35.53% | 德意志銀行 | →$250 | 開始承保 | →保留 |
| 12/02/2022 | -18.77% | KeyBanc | $350→$315 | 維護 | 超重 |
| 2022年11月30日 | -35.53% | 瑞銀集團 | →$250 | 開始承保 | →中性 |
| 10/28/2022 | -35.53% | B of A證券 | $385→$250 | 評級下調 | 購買→中性 |
| 10/28/2022 | -9.74% | KeyBanc | $400→$350 | 維護 | 超重 |
| 07/29/2022 | -11.03% | 斯蒂芬斯公司 | $330→$345 | 維護 | 等重 |
| 04/29/2022 | 5.73% | B of A證券 | $475→$410 | 維護 | 買 |
| 04/29/2022 | 3.15% | KeyBanc | $475→$400 | 維護 | 超重 |
| 2021/09/15 | 32.81% | B of A證券 | $450→$515 | 維護 | 買 |
| 07/30/2021 | 3.15% | 斯蒂芬斯公司 | $360→$400 | 維護 | 等重 |
| 07/30/2021 | 22.5% | KeyBanc | $350→$475 | 維護 | 超重 |
| 04/30/2021 | -12.32% | 斯蒂芬斯公司 | $315→$340 | 維護 | 等重 |
| 02/19/2021 | -18.77% | 斯蒂芬斯公司 | $300→$315 | 維護 | 等重 |
| 11/10/2020 | -9.74% | KeyBanc | →$350 | 開始承保 | →超重 |
| 10/14/2020 | -22.63% | 斯蒂芬斯公司 | →$300 | 開始承保 | →等重 |
| 04/24/2020 | - | B of A證券 | 升級 | 表現不佳的→中性 | |
| 2019年12月12日 | - | B of A證券 | 評級下調 | 中性→表現不佳 | |
| 2019年07月26日 | - | B of A證券 | 升級 | 表現不佳的→中性 | |
| 2019年05月01日 | - | 傑富瑞 | 評級下調 | 購買→Hold | |
| 2019年04月23日 | - | 威廉·布萊爾 | 開始承保 | →跑贏大盤 |
What is the target price for West Pharmaceutical Servs (WST)?
西部藥業Serv(WST)的目標價格是多少？
The latest price target for West Pharmaceutical Servs (NYSE: WST) was reported by Keybanc on August 21, 2023. The analyst firm set a price target for $415.00 expecting WST to rise to within 12 months (a possible 7.02% upside). 11 analyst firms have reported ratings in the last year.
Keybanc於2023年8月21日報道了West Pharmtics Serv(紐約證券交易所代碼：WST)的最新目標價。這家分析公司將目標價定為415.00美元，預計美國西部夏令時間將在12個月內上漲(可能上漲7.02%)。過去一年，有11家分析公司公佈了評級。
What is the most recent analyst rating for West Pharmaceutical Servs (WST)?
西部藥業Serv(WST)的最新分析師評級是多少？
The latest analyst rating for West Pharmaceutical Servs (NYSE: WST) was provided by Keybanc, and West Pharmaceutical Servs maintained their overweight rating.
對West Pharmtics Serv(紐約證券交易所代碼：WST)的最新分析師評級是由Keybanc提供的，West Pharmtics Serv維持其增持評級。
When is the next analyst rating going to be posted or updated for West Pharmaceutical Servs (WST)?
下一次分析師對西方製藥服務公司(WST)的評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of West Pharmaceutical Servs, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for West Pharmaceutical Servs was filed on August 21, 2023 so you should expect the next rating to be made available sometime around August 21, 2024.
分析師們在進行了廣泛的研究後得出了股票評級，其中包括查閱公共財務報表，與West Pharmtics Serv的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。對West Pharmtics Serv的最後一次評級是在2023年8月21日提交的，所以你應該預計下一次評級將在2024年8月21日左右的某個時候提供。
Is the Analyst Rating West Pharmaceutical Servs (WST) correct?
分析師對西方製藥服務公司(WST)的評級正確嗎？
While ratings are subjective and will change, the latest West Pharmaceutical Servs (WST) rating was a maintained with a price target of $385.00 to $415.00. The current price West Pharmaceutical Servs (WST) is trading at is $387.77, which is within the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的西方製藥服務公司(WST)的評級保持不變，目標價在385.00美元至415.00美元之間。西方醫藥公司目前的交易價格為387.77美元，在分析師的預測範圍內。